title: Pentoxifylline reduces the first-dose reactions following OKT3.
authors: Kidney Transplant Service, University of California, San Francisco 94143.
authors: F G
authors: FG
authors: Vincenti
authors: M
authors: M
authors: Vasconcelos
authors: J L
authors: JL
authors: Birnbaum
authors: S J
authors: SJ
authors: Tomlanovich
authors: W J
authors: WJ
authors: Amend
authors: J S
authors: JS
authors: Melzer
authors: J P
authors: JP
authors: Snyder
mesh_terms: D000082:Acetaminophen / Q000627:therapeutic use; D015703:Antigens, CD / Q000032:analysis; D001706:Biopsy; D017252:CD3 Complex / Q000032:analysis; D004155:Diphenhydramine / Q000627:therapeutic use; D006084:Graft Rejection / Q000473:pathology / Q000628:therapy*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D016853:Muromonab-CD3 / Q000009:adverse effects* / Q000627:therapeutic use; D010431:Pentoxifylline / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
chemical_list: D015703:Antigens, CD; D017252:CD3 Complex; D016853:Muromonab-CD3; D014409:Tumor Necrosis Factor-alpha; D000082:Acetaminophen; D004155:Diphenhydramine; D011239:Prednisolone; D010431:Pentoxifylline